Comparative Pharmacology
Head-to-head clinical analysis: EPITOL versus EQUETRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EPITOL versus EQUETRO.
EPITOL vs EQUETRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbamazepine stabilizes the inactivated state of voltage-gated sodium channels, thereby inhibiting high-frequency repetitive firing of action potentials and reducing synaptic transmission.
Equetro (carbamazepine extended-release) is an anticonvulsant and mood stabilizer. It stabilizes the inactivated state of voltage-gated sodium channels, thereby inhibiting repetitive neuronal firing and reducing synaptic transmission. It also potentiates GABA receptors and inhibits glutamate release.
Carbamazepine, immediate-release: initial 200 mg orally twice daily; increase by 200 mg/day at weekly intervals. Typical maintenance: 800-1200 mg/day in 2-3 divided doses. Extended-release: initial 200 mg orally twice daily; maintenance 400-600 mg twice daily.
Initial: 50 mg orally twice daily; increase by 50-100 mg/day every 2-4 weeks. Usual maintenance: 100-200 mg orally twice daily. Maximum: 200 mg orally twice daily.
None Documented
None Documented
20-40 hours (mean 30 hours); linear kinetics at therapeutic doses; decreased with concomitant enzyme-inducing drugs
Carbamazepine: 25-65 hours (initial single dose), 12-17 hours (chronic dosing due to autoinduction); carbamazepine-10,11-epoxide: 5-8 hours.
Renal: 70% (as glucuronide conjugates and other metabolites), Fecal: 30% (unchanged and metabolites)
Renal: 2% excreted unchanged (carbamazepine) in urine; 15% as carbamazepine-10,11-epoxide; 30% as other metabolites; biliary/fecal: 50-60% as metabolites.
Category C
Category C
Anticonvulsant
Anticonvulsant